For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Rapt Therapeutics, Inc.

USPTO Granted Patents = 13

EPO Patents = 2

Trademarks = 4

Forward Citations = 14

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

David Juergen Wustrow (12 out of 29 patents)

Mikhail Zibinsky (10 out of 24 patents)

Jeffrey J Jackson (8 out of 10 patents)

4. Akinori Okano (7 out of 7 patents)

5. Jacob Bradley Schwarz (7 out of 32 patents)

6. Ashkaan Younai (6 out of 8 patents)

7. John Michael Ketcham (6 out of 22 patents)

8. Parcharee Tivitmahaisoon (6 out of 14 patents)

9. Maureen Kay Reilly (5 out of 24 patents)

10. Omar Robles-Resendiz (5 out of 7 patents)

11. Dennis X Hu (5 out of 7 patents)

12. Grant Masaaki Shibuya (4 out of 8 patents)

13. Paul Robert Leger (4 out of 4 patents)

14. Omar Robles (4 out of 7 patents)

15. Jack Maung (3 out of 17 patents)

13 patents: Sort by Forward Citations

1. 12428393 - Methods of making trans isomeric forms of G protein-coupled receptor modulators (2025-09-30),

2. 12240837 - Chemokine receptor modulators and uses thereof (2025-03-04),

3. 12098139 - Chemokine receptor modulators and uses thereof (2024-09-24),

4. 12006318 - Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof (2024-06-11),

5. 11918582 - Pyrazole pyrimidine compounds and uses thereof (2024-03-05),

6. 11730736 - Anticancer agents (2023-08-22),

7. 11384064 - Chemokine receptor modulators and uses thereof (2022-07-12),

8. 11192879 - Chemokine receptor modulators and uses thereof (2021-12-07),

9. 11084829 - Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof (2021-08-10),

10. 11046699 - Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses (2021-06-29),

11. 10722514 - Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof (2020-07-28),

12. 10683280 - Chemokine receptor modulators and uses thereof (2020-06-16),

13. 10604526 - Chemokine receptor modulators and uses thereof (2020-03-31),

Rapt Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing small molecule therapies for patients with cancer. The company's lead drug candidate, FLX475, is currently in clinical trials for a variety of solid tumors. Rapt Therapeutics is dedicated to advancing innovative therapies to improve outcomes for cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

13 Patents

#80 in South San Francisco, CA

#5,489 in California

#23,148 in US

#43,689 in the World

South San Francisco, CA, United States of America

Rapt Therapeutics, Inc.

Forward Citations = 14

45 inventors:

David Juergen Wustrow (12 out of 29 patents)

Mikhail Zibinsky (10 out of 24 patents)

Jeffrey J Jackson (8 out of 10 patents)

4. Akinori Okano (7 out of 7 patents)

5. Jacob Bradley Schwarz (7 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…